Resources
- sort by:
- Relevance
- Date
- Popularity
- Study of Claims Data Finds REMICADE Dosing Remains Stable with Maintenance Therapy over Two Year Period
- ORLANDO, Fla. -- Headline of release should read: Study of Claims Data Finds REMICADE Dosing Remains Stable with Maintenance Therapy over Two Year Period sted Study of Claims Data Finds REMICADE Dosing Remains Stable with Maintenace Therapy over Two Year Period. The corrected release reads: STUDY OF CLAIMS...
- Research articles 2004-11-02
- MabThera Maintenance Therapy Dramatically Improves Survival for Patients With Lymphoma.
- BASEL, Switzerland, December 12 /PRNewswire/ -- - Risk of Death Halved - Roche Files Label Extension in Europe for Maintenance Therapy Two years of maintenance therapy with MabThera rituximab dramatically improves the chances of survival for patients suffering from one of...
- Research articles 2005-12-12
- REMICADE® Phase 3 Data Show Rapid and Significant Improvement and Long-Term Response in the Treatment of Moderate to Severe Psoriasis; Findings from Two Phase 3 Studies Show High-Level, Sustained Response with Maintenance Therapy
- SAN FRANCISCO -- Phase 3 data show treatment with REMICADER infliximab resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the EXPRESS II trial, a placebo-controlled, dose-ranging study of REMICADE 3 mg/kg and 5 mg/kg, showed that every eight week maintenance...
- Research articles 2006-03-06
- Industry is on Board with Lung Cancer Maintenance, but are Docs?
- The FDA approved Eli Lilly’s chemotherapy drug Alimta pemetrexed as the first maintenance therapy for lung cancer, but as Lilly admits in its press release, the concept of maintenance therapy is not one lung cancer docs are familiar with. by Trista Morrison
- Blog posts 2009-07-10
- AMAG Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions Your first question comes from the line of Soham Pandya of ThinkEquity. Soham Pandya - ThinkEquity Great, thanks for taking my question. Brian just a couple of quick question; you mentioned about learning more about the European strategy maybe the partnerships or distribution agreement,...
- Earnings calls 2008-06-23
- OSI Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you sir. The Question and Answer Session will be conducted electronically. Operator instructions We will take our first question from Geoffrey Meacham, with JPMorgan. Please go ahead. [Terry - JPMorgan Chase & Co.] Hey, guys. This is Terry calling in...
- Earnings calls 2008-10-22
- American Shared Hospital Services Will Provide Latest Image-Guided Radiation Therapy System to Tufts-New England Medical Center as Part of a Complete Radiation Therapy Department Upgrade
- SAN FRANCISCO -- American Shared Hospital Services (AMEX:AMS)(PCX:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into a letter of understanding to provide an image-guided radiation therapy IGRT system, a CT Simulator, and related service, support and maintenance...
- Research articles 2006-06-01
- Savient Pharmaceuticals, Inc, Q4 Year Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions And we'll go first to Eric Varma with Leerwink Swann. Eric Varma – Leerwink Swann Hey, good morning I had a quick question on a follow-on about febuxostat. If you can just kind of remind us how the CV incidents compare between...
- Earnings calls 2009-02-26
- Maintenance fluconazole checks recurrent candidiasis; use in relapse after azole therapy
- WASHINGTON -- New data from two studies suggest that there is hope for women with complicated vulvovaginal candidiasis, Dr. Jack D. Sobel said at an update on sexually transmitted diseases sponsored by OB.GYN. NEWS and Boston University. Maintenance prophylaxis with fluconazole appears to benefit women who typically relapse following...
- Research articles 2003-10-01
- OSI Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript
- Question-and-Answer Session Operator Thank you. Operator Instructions And first we'll hear from Terence Quinn with JP Morgan. Terence Quinn – JPMorgan Hi guys thanks for taking the question. I mean for just yesterday just I have a question on the maintenance opportunity I'm wondering Gabe and Colin...
- Earnings calls 2009-02-19
- Aetna limits breast cancer marrow therapy.(Brief Article)
- BLUE BELL, Pa.-Aetna U.S. Healthcare said last week it will limit coverage of a particular treatment for advanced breast cancer because researchers have failed to establish its effectiveness. Meanwhile, other health maintenance organizations say th BLUE BELL, Pa.-Aetna U.S. Healthcare said last week it...
- Research articles 2000-02-21
- OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen® Maintenance Trial in Neovascular Age-Related Macular Degeneration
- NEW YORK -- Trial to Study Whether Use of Macugen Following Neovascular AMD Therapy Provides a Balance in Long-Term Safety and Efficacy
- Research articles 2006-06-26
- Health Net to Offer Acupuncture, Massage Therapy, Acupressure Benefit
- WOODLAND HILLS, Calif.--BW HealthWire--Sept. 9, 1997--Health Net, one of California's largest health maintenance organizations HMOs, will offer direct access to acupuncture treatment as the next step in a planned expansion of its complementary and alternative medicine coverage, subject to California State Department of Corporations DOC approval.
- Research articles 1997-09-09
- Facet Biotech: Value Investing with a Catalyst
- ValueHuntr submits: We are adding Facet Biotech Corporation to our ValueHuntr Portfolio. FACT is a company with a market cap of $239M ($9.72/share) with $295M ($12.00/share) of net-cash as of December 31, 2008. On December 18, 2008, Facet Biotech completed its spin-off from PDL BioPharma, Inc. PDL. PDL capitalized Facet...
- External links 2009-04-15
- Mesalamine shown effective in microscopic colitis: continuation of open-label study
- ORLANDO, FLA. -- Mesalamine produced clinical and histologic remission of microscopic colitis and obviated the need for maintenance therapy in most patients, Dr. Charles W. Randall reported at Digestive Disease Week 2003. Researchers and clinicians are increasingly implicating microscopic colitis, which includes lymphocytic colitis and collagenous colitis, as a...
- Research articles 2003-10-15
- Centocor Presents Long-Term Data From Accent II Trial With Remicade(R) (infliximab) In Maintaining Fistula Closures In Crohn's Patients
- New 54-week data from the ACCENT II clinical trial assessing the effectiveness of maintenance therapy with REMICADER infliximab in sustaining closure of draining fistulas in Crohn's disease CD were reported today at the Digestive Disease Week meeting in San Francisco. Up to 30 percent of patients who have CD, a...
- Research articles 1970-01-01
- Epicept Still Searching for Partner to Help Launch Its Latest Drug
- VFC submits: Epicept Corporation EPCT announced on Tuesday that a partner has been found for Ceplene, the company's drug that is approved in the European Union for maintenance therapy for adult patients with AML in first remission. However, the partnership agreement is not in preparation for the commercial launch...
- External links 2009-06-03
- Becton Dickinson F3Q07 (Qtr End 6/30/07) Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions And we'll go to the line of Mike Weinstein from J.P. Morgan. Please go ahead. Mike Weinstein - J.P. Morgan Thank you for taking the questions, good morning. I'd like to start on the MRSA opportunity, I think on our last update, you'd commented that...
- Earnings calls 2007-07-26
- Eli Lilly Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions And our first question comes from the line of James Kelly of Goldman Sachs. Please go ahead. James Kelly - Goldman Sachs Thank you and good morning. My question relates to Zyprexa and the depot formulation, and thank you for the additional data in Canada...
- Earnings calls 2007-07-24
- Celgene Corp. Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you very much. (Operator's Instructions). And we will go first to Geoffrey Meacham at JPMorgan. Geoffrey Meacham – JPMorgan Hi, guys. Thanks for taking the question. A couple of financial questions, maybe one for Dave; can you help us with the co...
- Earnings calls 2009-01-29
- << Previous
- page 1 of 2
- Next >>
